Literature DB >> 6547378

Oxalate absorption and postprandial urine supersaturation in an experimental human model of absorptive hypercalciuria.

S B Erickson, K Cooper, A E Broadus, L H Smith, P G Werness, H J Binder, J W Dobbins.   

Abstract

The effect of 1.25-dihydroxyvitamin D [1,25-(OH)2D] on dietary oxalate absorption and postprandial urine supersaturation with calcium oxalate was determined in 11 normal subjects. 1,25-(OH)2D increased the urinary excretion of orally administered [14C]oxalate in the 8 h period after a liquid meal containing 1.875 mmol of calcium and 0.83 mmol of oxalate (P less than 0.01), and during a 48 h period when the subjects ingested a diet containing 25 mmol of calcium and 3.3 mmol of oxalate/day (P less than 0.01); however, 1,25-(OH)2D administration had no effect on [14C]oxalate excretion when calcium was removed from the liquid meal. 1.25-(OH)2D increased 24 h urinary oxalate excretion from 28.7 +/- 2.1 mmol/mol of creatinine to 36.8 +/- 2.6 mmol/mol of creatinine (P less than 0.05) on the 10 mmol/day calcium diet and from 26.4 +/- 2.9 to 33.2 +/- 2.2 mmol/mol of creatinine (P less than 0.1) on the 25 mmol/day calcium diet. A linear correlation (r = 0.72) was found between plasma 1,25-(OH)2D levels and urinary [14C]oxalate excretion after the liquid meal. 1,25-(OH)2D administration produced postprandial supersaturation of urine with calcium oxalate and calcium oxalate crystalluria. These studies suggest that 1,25-(OH)2D increases oxalate absorption (and urinary excretion) by increasing calcium absorption, which results in less binding of calcium to oxalate in the intestine; therefore more oxalate is available for absorption. The combined effect of increased calcium and oxalate absorption results in postprandial supersaturation of urine with calcium oxalate, with resultant crystalluria.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6547378     DOI: 10.1042/cs0670131

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  6 in total

1.  Artificial neural networks for assessing the risk of urinary calcium stone among men.

Authors:  Bertrand Dussol; Jean-Michel Verdier; Jean-Marc Le Goff; Patrice Berthezene; Yvon Berland
Journal:  Urol Res       Date:  2006-01-06

2.  Oxalate transport by anion exchange across rabbit ileal brush border.

Authors:  R G Knickelbein; P S Aronson; J W Dobbins
Journal:  J Clin Invest       Date:  1986-01       Impact factor: 14.808

3.  An assessment of parathyroid hormone, calcitonin, 1,25 (OH)2 vitamin D3, estradiol and testosterone in men with active calcium stone disease and evaluation of its biochemical risk factors.

Authors:  Nasser Shakhssalim; Kobra Roohi Gilani; Mahmoud Parvin; Peyman Mohammadi Torbati; Amir H Kashi; Mohaddeseh Azadvari; Banafsheh Golestan; Abbas Basiri
Journal:  Urol Res       Date:  2010-05-19

4.  A patient with hypophosphatemia, a femoral fracture, and recurrent kidney stones: report of a novel mutation in SLC34A3.

Authors:  Kathleen Page; Clemens Bergwitz; Graciana Jaureguiberry; Chittari V Harinarayan; Karl Insogna
Journal:  Endocr Pract       Date:  2008-10       Impact factor: 3.443

Review 5.  Dietary recommendations and treatment of patients with recurrent idiopathic calcium stone disease.

Authors:  W G Robertson
Journal:  Urolithiasis       Date:  2015-12-08       Impact factor: 3.436

6.  Oxalobacter formigenes may reduce the risk of calcium oxalate kidney stones.

Authors:  David W Kaufman; Judith P Kelly; Gary C Curhan; Theresa E Anderson; Stephen P Dretler; Glenn M Preminger; David R Cave
Journal:  J Am Soc Nephrol       Date:  2008-03-05       Impact factor: 10.121

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.